120 related articles for article (PubMed ID: 2550684)
1. [The accuracy of CT and tumor markers in the detection of a recurrent ovarian carcinoma].
Wakabayashi Y; Ishida J; Kotake F; Hirose M; Kawana K; Abe K; Amino S; Negishi Y; Akiya K
Gan No Rinsho; 1989 Sep; 35(10):1127-31. PubMed ID: 2550684
[TBL] [Abstract][Full Text] [Related]
2. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer.
Sugiyama T; Nishida T; Komai K; Nishimura H; Yakushiji M; Nishimura H
Int J Gynaecol Obstet; 1996 Sep; 54(3):251-6. PubMed ID: 8889633
[TBL] [Abstract][Full Text] [Related]
3. [Ovarian cancer--a comparison between CT diagnosis and serum tumor markers].
Wakabayashi Y; Yachida M; Akata S; Kawana K; Kotake F; Kakizaki D; Abe K; Negishi N; Akiya K
Gan No Rinsho; 1988 Jan; 34(1):52-6. PubMed ID: 3422324
[TBL] [Abstract][Full Text] [Related]
4. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer.
Pan HS; Lee SL; Huang LW; Chen YK
Arch Gynecol Obstet; 2011 Feb; 283(2):335-41. PubMed ID: 20221620
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors.
Zanetta G; Rota S; Lissoni A; Meni A; Brancatelli G; Buda A
Gynecol Oncol; 2001 Apr; 81(1):63-6. PubMed ID: 11277651
[TBL] [Abstract][Full Text] [Related]
6. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma.
Martínez-Román S; Ramirez PT; Oh J; Viciedo MG; MacApinlac HA
Gynecol Oncol; 2005 Mar; 96(3):888-91. PubMed ID: 15721446
[TBL] [Abstract][Full Text] [Related]
7. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
Fularz M; Adamiak P; Czepczyński R; Jarząbek-Bielecka G; Rewers A; Kędzia W; Ruchała M
Nuklearmedizin; 2015; 54(4):158-62. PubMed ID: 26076719
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of magnetic resonance imaging for the detection of tumor recurrence in patients with carcinoma of the ovaries.
Kainz C; Prayer L; Gitsch G; Stiglbauer R; Kramer J; Reinthaller A; Kölbl H
J Am Coll Surg; 1994 Mar; 178(3):239-44. PubMed ID: 8149015
[TBL] [Abstract][Full Text] [Related]
9. Computed tomography of the gastrointestinal tract.
Lee KR
Crit Rev Diagn Imaging; 1982; 18(2):121-65. PubMed ID: 6290141
[No Abstract] [Full Text] [Related]
10. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
11. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
Markman M
Gynecol Oncol; 2006 Jun; 101(3):550-1; author reply 551-2. PubMed ID: 16540155
[No Abstract] [Full Text] [Related]
12. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer.
Prayer L; Kainz C; Kramer J; Stiglbauer R; Schurawitzki H; Baldt M; Schima W; Poelzleitner D; Reinthaller A; Koelbl H
J Comput Assist Tomogr; 1993; 17(4):626-32. PubMed ID: 8331235
[TBL] [Abstract][Full Text] [Related]
13. The role of CT in the evaluation of ovarian malignancy.
Amendola MA
Crit Rev Diagn Imaging; 1985; 24(4):329-68. PubMed ID: 3896652
[TBL] [Abstract][Full Text] [Related]
14. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
Sevinc A; Camci C; Turk HM; Buyukberber S
Oncology; 2003; 65(1):1-6. PubMed ID: 12837976
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer.
Lenhard SM; Burges A; Johnson TR; Kirschenhofer A; Bruns C; Linke R; Friese K
Eur J Obstet Gynecol Reprod Biol; 2008 Oct; 140(2):263-8. PubMed ID: 18614272
[TBL] [Abstract][Full Text] [Related]
17. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
18. A giant ovarian mucinous tumor in a 58-year-old postmenopausal patient with persistent abdominal pain and high serum levels of CA 19-9.
Mulita F; Oikonomou N; Tchabashvili L; Liolis E; Kehagias I
Pan Afr Med J; 2020; 37():76. PubMed ID: 33244339
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.
Chung HH; Kwon HW; Kang KW; Park NH; Song YS; Chung JK; Kang SB; Kim JW
Ann Surg Oncol; 2012 Jun; 19(6):1966-72. PubMed ID: 22124757
[TBL] [Abstract][Full Text] [Related]
20. [Clinical usefulness of serum sialyl Le(x)-i measurement in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):15-9. PubMed ID: 2564410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
